US4634666A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human-murine hybridoma fusion partner
Assignee: Leland Stanford Junior University
•
Filing: 1984-01-06
•
Granted: 1987-01-06
•
Expires: 2004-01-06
Abstract
Abstract By careful screening and mutation, a human-murine hybridoma suitable as a fusion partner for immortalizing an antibody-secreting B cell has been generated. The trioma fusion products of this immortalizing partner are stable producers of human monoclonal antibodies. A trioma which produces monoclonal human anti-varicella zoster is disclosed.
Inventors
- 👤 Edgar G. Engleman
- 👤 Steven K. H. Foung
- 👤 F. Carl Grumet
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 23:20
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/34; C12; C12N; C12N5/00; C12N5/10; C12N5/12; C12N5/16; C12N5/166; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/80; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
84 words
An immortalizing fusion partner for use in producing a trioma cell line capable of secreting a human monoclonal antibody specific against a selected antigen, when fused with a non-malignant b-lymphoid cell derived from a human donor exposed to such antigen, comprising a fused mouse myeloma/non-malignant human B-lymphocyte cell line which (a) expresses HLA surface antigens, (b) does not secrete immunoglobulins, and (c) is deficient in hypoxanthine phosphoribosyl transferase, as evidenced by the inability of the cell line to grow in hypoxanthine-aminopterin-thymidine or azaserine-hypoxanthine medium.
Claim 2
Dependent Claim
84 words
An immortalizing fusion partner for use in producing a trioma cell line capable of secreting a human monoclonal antibody specific against a selected antigen, when fused with a non-malignant b-lymphoid cell derived from a human donor exposed to such antigen, comprising a fused mouse myeloma/non-malignant human B-lymphocyte cell line which (a) expresses HLA surface antigens, (b) does not secrete immunoglobulins, and (c) is deficient in hypoxanthine phosphoribosyl transferase, as evidenced by the inability of the cell line to grow in hypoxanthine-aminopterin-thymidine or azaserine-hypoxanthine medium.
Claim 3
Dependent Claim
14 words
The fusion partner of claim 1, which has the characteristics of ATCC HB 8464.
Claim 4
Dependent Claim
85 words
A trioma cell line capable of secreting a normal human monoclonal antibody specific against a selected antigen, said cell line comprising the fusion product of: (1) a mouse myeloma/non-malignant human B-lymphocyte hybridoma fusion partner which (a) expresses HLA surface antigens, (b) does not secrete immunoglobulins, and (c) is deficient in hypoxanthine phosphoribosyl transferase, as evidenced by the inability of the fusion partner to grow in hypoxanthine-aminopterin-thymidine or azaserine-hypoxanthine medium, and (2) a non-malignant B-lymphoid cell derived from a human donor exposed to the selected antigen.
Claim 5
Dependent Claim
85 words
A trioma cell line capable of secreting a normal human monoclonal antibody specific against a selected antigen, said cell line comprising the fusion product of: (1) a mouse myeloma/non-malignant human B-lymphocyte hybridoma fusion partner which (a) expresses HLA surface antigens, (b) does not secrete immunoglobulins, and (c) is deficient in hypoxanthine phosphoribosyl transferase, as evidenced by the inability of the fusion partner to grow in hypoxanthine-aminopterin-thymidine or azaserine-hypoxanthine medium, and (2) a non-malignant B-lymphoid cell derived from a human donor exposed to the selected antigen.
Claim 6
Dependent Claim
40 words
The cell line of claim 3, for use in producing a monoclonal antibody which is immunoreactive with a microorganism known to cause acute infection in humans, wherein the B-lymphoid cell is derived from a human having such an acute infection.
Claim 7
Dependent Claim
34 words
The cell line of claim 4, for use in forming an antibody which is immunoreactive with varicella-zoster virus, wherein the B-lymphoid cell is derived from a human having an acute varicella zoster viral infection.
Claim 8
Dependent Claim
14 words
The cell line of claim 5, which has the characteristics of ATCC HB 8463.
Claim 9
Dependent Claim
45 words
The cell line of claim 3, wherein the lymphoid cell is stimulated in vitro under conditions which promote lymphoid cell growth in such medium, and the fusion partner is also resistant to a drug at a concentration which prevents growth of the stimulated lymphoid cell.
Claim 10
Dependent Claim
26 words
The cell line of claim 7, wherein the lymphoid cell is stimulated with Epstein-Barr virus, and the fusion partner is resistant to about 1 μM ouabain.
Claim 11
Independent Claim
135 words
A method of producing a human monoclonal antibody which is specific against a selected antigen, comprising providing a fusion partner produced by fusing mouse myeloma cells and non-malignant human B-lymphocytes, selecting fusion products which show stable immunoglobulin secretion and HLA surface antigen production in culture, treating the selected fusion products with a mutagen, and selecting mutagenized fusion products which retain the ability to produce HLA surface antigen, show no immunoglobulin secretion, and are unable to survive in a growth medium which allows growth of a successful fusion product formed by fusing the fusion partner with a human immunoglobulin-secreting B-lymphoid cell, fusing the fusion partner with a non-malignant B-lymphoid cell derived from a human donor exposed to the selected antigen, and selecting fusion products which are viable in such medium and which secrete antigen-specific monoclonal antibody.
Claim 12
Independent Claim
135 words
A method of producing a human monoclonal antibody which is specific against a selected antigen, comprising providing a fusion partner produced by fusing mouse myeloma cells and non-malignant human B-lymphocytes, selecting fusion products which show stable immunoglobulin secretion and HLA surface antigen production in culture, treating the selected fusion products with a mutagen, and selecting mutagenized fusion products which retain the ability to produce HLA surface antigen, show no immunoglobulin secretion, and are unable to survive in a growth medium which allows growth of a successful fusion product formed by fusing the fusion partner with a human immunoglobulin-secreting B-lymphoid cell, fusing the fusion partner with a non-malignant B-lymphoid cell derived from a human donor exposed to the selected antigen, and selecting fusion products which are viable in such medium and which secrete antigen-specific monoclonal antibody.
Claim 13
Dependent Claim
16 words
The method of claim 9, wherein the fusion partner has the characteristics of ATCC HB 8464.
Claim 14
Dependent Claim
36 words
The method of claim 9, for producing a monoclonal antibody which is immunoreactive against a microorganism known to cause acute infection in humans, wherein the B-lymphoid cells are derived from a human with said acute infection.
Claim 15
Dependent Claim
35 words
The method of claim 11, for producing a monoclonal antibody which is immunoreactive with varicella zoster virus antigen, wherein the B-lymphoid cells are derived from a human donor having an acute varicella zoster virus infection.
Claim 16
Independent Claim
29 words
The method of claim: 12, wherein the antibody is made by a fusion product of the fusion partner and the B-lymphoid cells having the characteristics of ATCC HB 8463.
Claim 17
Dependent Claim
42 words
The method of claim 10, which further includes stimulating the human B-lymphoid cells in vitro prior to said fusing, and the fusion partner is also resistant to a drug at a concentration which prevents growth of the stimulated lymphocyte in said medium.
References Cited (Backward Citations)
US4444887A
Cited
US4472500A
Cited
US4430437A
Cited
US4451570A
Cited
US4474893A
Cited
US4434230A
Cited
GB2113715A
Cited
US4464465A
Cited
US4529694A
Cited
US4574116A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-01-05 | 1990-07-07 | 1991-01-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-01-05 | 1994-07-07 | 1995-01-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-01-05 | 1998-07-07 | 1999-01-06 | $7700.00 | Window Closed / Lapsed |